TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05107492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 450mg
Description: following a single subcutaneous dose of PF-06480605 450 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150mg
Description: following a single subcutaneous dose of PF-06480605 150 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: following a single subcutaneous dose of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: following a single subcutaneous dose of placebo
Study: NCT06113965

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Stimulation
Description: Electrical stimulation of peripheral nerves to measure resulting gait kinematics and surface muscle activity
Study: NCT06123221

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osseodensification with Versah system
Description: Access to the bone crest will be performed through a slightly palatinized crestal incision, and a full-thickness mucoperiosteal flap will be elevated. Implant site preparation will be performed according to the bone densification drilling sequence established by the Densah® technique protocol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral window
Description: A full-thickness mucoperiosteal flap will be elevated. The lateral window will be made with a spherical diamond drill (number 8) at 20,000 rpm. The mesiodistal and apicocoronal dimensions of the lateral access window to the sinus will be measured in all the participants using a caliper. Sinus membrane elevation will be performed with manual instruments.
Study: NCT06164041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The use of mobile applications promoted from the physical education classroom to improve adolescent health.
Description: Before starting the intervention, a total of 465 adolescents participated in pretest measurements (T1).~Researchers in charge of explaining how the apps worked were not involved in the measurements or subsequent analysis, as they knew which student belonged to each App and control group. Once each app had been described and its use explained, a training plan was drawn up to be followed during the period of mandatory use.~The adolescents were motivated to utilize the app for a duration of ten weeks, aiming for a minimum usage of three times per week.~After the mandatory intervention with the mobile apps, post-test measurements were carried out (T2). Then, a period of 10 weeks was provided in which the use of the app was neither mandatory nor promoted from the physical education subject, after which the post-test 2 measurements (T3) were taken.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The use of mobile applications promoted from the physical education classroom to improve adolescent health.
Description: Before starting the intervention, a total of 465 adolescents participated in pretest measurements (T1).~Researchers in charge of explaining how the apps worked were not involved in the measurements or subsequent analysis, as they knew which student belonged to each App and control group. Once each app had been described and its use explained, a training plan was drawn up to be followed during the period of mandatory use.~The adolescents were motivated to utilize the app for a duration of ten weeks, aiming for a minimum usage of three times per week.~After the mandatory intervention with the mobile apps, post-test measurements were carried out (T2). Then, a period of 10 weeks was provided in which the use of the app was neither mandatory nor promoted from the physical education subject, after which the post-test 2 measurements (T3) were taken.
Study: NCT05497479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.003% AR-15512 to be administered in both eyes
Description: Two rounds of Schirmer tests, performed without anesthetic (per randomization), before and after instillation of 0.003% AR-15512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle to be administered in both eyes
Description: Two rounds of Schirmer tests, performed without anesthetic, before and after instillation of Vehicle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.003% AR-15512 to be administered in both eyes
Description: Two rounds of Schirmer tests, performed with anesthetic (per randomization), before and after instillation of 0.003% AR-15512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle to be administered in both eyes
Description: Two rounds of Schirmer tests, performed with anesthetic (per randomization), before and after instillation of Vehicle
Study: NCT05081479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: N-AC infusion will begin the day before CAR T cell infusion and continuously infused over 24-hours for 14 days or until time of discharge whichever is earlier. Interruptions of N-AC infusion for medical reasons are permissible. The dose for patients \<45kg will be adjusted to weight based dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: N-AC infusion will begin the day before CAR T cell infusion and continuously infused over 24-hours for 14 days or until time of discharge whichever is earlier. Interruptions of N-AC infusion for medical reasons are permissible. The dose for patients \<45kg will be adjusted to weight based dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: N-AC infusion will begin the day before CAR T cell infusion and continuously infused over 24-hours for 14 days or until time of discharge whichever is earlier. Interruptions of N-AC infusion for medical reasons are permissible. The dose for patients \<45kg will be adjusted to weight based dosing.
Study: NCT06293209

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3M cold pack
Description: 3M cold pack
Study: NCT05294692

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Health Incentives
Description: Caterpillar Health (Caterpillar Health Inc., Leeds, UK) is a multi-component healthy living app that includes financial incentive (points redeemable for consumer goods like movies or gym passes) and was made available to Leeds, UK residents on the Apple iTunes/App Store and Google Play app stores on August 8, 2022. The app was later made available to all of the UK as of October 3, 2022. The app uses the smartphone's in-built accelerometer and/or is integrated with Apple Health and Google Fit to promote physical activity through step tracking. To offer a variety of popular incentives, Caterpillar Health formed partnerships with two major UK based companies, Vue Cinema and Hussle (a gym network system), allowing users to redeem points for free movie and gym passes. Additionally, the company collaborated with a UK health agency (Active Leeds via Leeds City Council) to assist in the development and approval of educational health quiz content.
Study: NCT05521698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05220670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT
Description: It will be carried out after a 10-minute warm-up period with joint mobility exercises and dynamic stretching. The intervention will consist of a training in which intense work intervals and active rest periods are combined using a cycle ergometer. The session will be divided into 4 intervals of 4 minutes duration at an intensity of 85-95% of the maximum heart rate \[MHR\], individually controlled during all sessions (Polar Team pro®), followed by active rest intervals of 3 minutes duration at 50-70% FCM. After training, a 10-minute cool-down of gentle pedaling and joint range exercises will be carried out.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MICT
Description: Heating phase identical to the previous one. Subsequently, the participants will perform training on the cycle ergometer with an intensity close to 70% FCM maintained for 40 minutes and will be individually controlled (Polar Team pro®). The session will conclude with a cool-down phase identical to the previous one.
Study: NCT05521698

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transurethral Resection of Bladder Tumor
Description: Undergo TURBT

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transurethral Resection of Bladder Tumor
Description: Undergo TURBT
Study: NCT05139303

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthoapnea NOA®
Description: The efficacy of the appliance for the management of OSA will be stablished based on two criteria. Criterion I: \> 50% reduction of AHI/RDI. Criterion II: AHI/RDI \< 5 events/hour or \<15 events/hour with a significative reduction of OSA associates symptoms as defined before. Therapeutic failure will be established when at 100% of advancement of the device, there is less than 50% of reduction of the AHI/RDI with a residual AHI/RDI \>5 events/hour with OSA associates symptoms.
Study: NCT04916626

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OPUS YOUNG
Description: OPUS YOUNG is a two year out-patient specialized early intervention service for children and adolescents with a first episode psychosis. The OPUS YOUNG treatment consists of the following elements: modified assertive community treatment, low patients to case manager ratio, cognitive-behavioural case management (CBCM), psycho-educational family treatment including multiple family groups(MFG) and psychoeducational siblings groups, Social Cognition and Interaction Training (SCIT), possible individual Cognitive Behavioural Therapy (CBT) in addition to CBCM, and manual based psychopharmacologic treatment. Additional, special transition support, individual school/employment support, and prevention and treatment of substance abuse.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: The patients allocated to TAU will be offered non-manualized treatment following national Danish guidelines and local guidelines. Treatment is provided by a multidisciplinary team and consists of case-management (no defined upper case load), family support and psychoeducation, in addition to psychopharmacological treatment. In some cases, social skills training and CBT may be offered. In general, office visits take place in outpatient clinics.
Study: NCT05308199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: thoracic manipulation
Description: thoracic manipulation for unlocking of facet joints
Study: NCT06293209

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Perskindol cold spray
Description: Perskindol cold spray

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04707625

Intervention type: DRUG
Group type: OTHER
Intervention: Aflibercept Ophthalmic
Description: Anti-vascular endothelial growth factor intraocular injection
Study: NCT06329596

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Xylitol gum
Description: Two pieces of xylitol gum after meals, thrice a day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sorbitol gum
Description: Two pieces of sorbitol gum after meals, thrice a day.
Study: NCT05771701

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pain pressure threshold measurement
Description: Pain pressure threshold (PPT) is used to measure deep muscular tissue sensitivity. The test determines the amount of pressure over a given area in which a steadily increasing nonpainful pressure stimulus turns into a painful pressure sensation. A varying pressure is applied from 0.5 to 1 kg/sec in a perpendicular direction relative to the muscle. PPT has no standard protocol on administration and placement. Equipment used varies with many handheld electric algometers.~PPT has been used on a wide variety of patients and conditions, including musculoskeletal and neuromuscular disorders (eg, Parkinson disease, tension headaches, pelvic pain, low back pain, myofascial trigger points, sacroiliac joint pain, knee osteoarthritis, skin humidity, shoulder pain, lateral epicondylitis).
Study: NCT06166745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensi-IP toothpaste
Description: Brushing daily with the Sensi-IP toothpaste for 14 days for dentinal hypersensitivity.
Study: NCT05734963

Intervention type: GENETIC
Intervention: DNA sequencing, RNA gene expression analysis, molecular profiling
Description: Growth of organoids from tissue samples, collection of tissue, blood and saliva samples for DNA sequencing, RNA gene expression analysis, molecular profiling
Study: NCT06225102

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kegel Exercise
Description: * Before teaching Kegel exercises, it was recommended that the person empty his bladder and wear comfortable clothing.~* It was said that the person should extend his legs straight while exercising and not to contract his leg, hip and abdominal muscles and not to hold his breath while the pelvic floor muscles contract.~* The relevant muscles were told to contract for 10 seconds and then relax for 10 seconds. The person was also asked to do the exercises during daily activities.~* Exercise was implemented regularly 3 times a day (minimum 30-45 exercises) in the morning, noon and evening.
Study: NCT04670900

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tension band wiring or plate fixation
Description: Choice of operative treatment is TBW or PF with a precontoured anatomical plate. The treating surgeon decides if TBW or PF is chosen as operative treatment method. The surgeries are performed according to OTA principles by an experienced surgeon, a trauma fellow or a consultant as approved by the participating hospitals.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active non-operative treatment with optional plaster cast
Description: Patients allocated to non-operative treatment are offered a back-slab in 60 degrees of flexion for pain-relief. The back-slab is removed 7-14 days following injury.
Study: NCT05727722

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: a single course of micro-encapsulated hepatocytes intraperitoneal transplantation therapy
Description: A single course will be divided into an accelerated titration design phase and a 3+3 design phase to reduce the number of subjects exposed to potentially ineffective doses that may not benefit from treatment. The accelerated titration design phase starts at a starting dose of 0.15x10\^9, moving to the 3+3 design phase at the dose of 0.5x10\^9. According to the semi-logarithmic incremental (10\^0.5-fold) approach, the treatment dosage was set into four groups at a maximum dose of 4.5×10\^9 (allowing for a ±20% difference between the actual dose and the planned dose, considering production specifics). The number or the incremental ratio of subsequent dose groups can be adjusted based on the evaluation of available data in the study, and intermediate doses can be explored.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: a single course of micro-encapsulated hepatocytes intraperitoneal transplantation therapy
Description: A single course will be divided into an accelerated titration design phase and a 3+3 design phase to reduce the number of subjects exposed to potentially ineffective doses that may not benefit from treatment. The accelerated titration design phase starts at a starting dose of 0.15x10\^9, moving to the 3+3 design phase at the dose of 0.5x10\^9. According to the semi-logarithmic incremental (10\^0.5-fold) approach, the treatment dosage was set into four groups at a maximum dose of 4.5×10\^9 (allowing for a ±20% difference between the actual dose and the planned dose, considering production specifics). The number or the incremental ratio of subsequent dose groups can be adjusted based on the evaluation of available data in the study, and intermediate doses can be explored.
Study: NCT06166745

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Fluoride Toothpaste
Description: Brushing daily with the Sodium Fluoride toothpaste for 14 days for dentinal hypersensitivity.
Study: NCT06090916

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard nutrition care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Participate in weekly support sessions with diet prescription

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Chart Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device Usage and Evaluation
Description: Record dietary and physical activity using MyFitnessPal smartphone app

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Record dietary and physical activity using MyFitnessPal smartphone app
Study: NCT05308199

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: muscle enegy technique
Description: to release muscle spasm of cervical musces
Study: NCT04955379

Intervention type: DEVICE
Group type: OTHER
Intervention: EQ103
Description: Ophthalmic Refractometer with a measurement and background channel
Study: NCT05518942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sensorimotor rhythm neurofeedback training
Description: In this study, baseline brain waves will be recorded for 5 minutes before each treatment, and the average value of SMR waves was used as the basis for setting the treatment threshold for the week. During the treatment, the subjects are arranged to sit in front of a computer screen with a game or animation playing. The individual focuses on the games or animations on the screen. The software will analyze the brain wave signals from the brain and convert them into visual and auditory feedback on the computer screen. Clients can learn to control brain activity and give visual and auditory feedback when a set threshold is reached
Study: NCT06090916

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Assessment
Description: Undergo malnutrition screening

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05128643

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant novel coronavirus vaccine (CHO cell)
Description: Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Recombinant novel coronavirus vaccine (CHO cells).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant novel coronavirus vaccine (CHO cell)
Description: Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Recombinant novel coronavirus vaccine (CHO cells).
Study: NCT06255392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Fluzoparib capsules appropriate dose oral, each treatment cycle defined as 3 weeks (21 days).
Study: NCT05216952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal Acetate Tablets
Description: 90mg (three 30mg tablets) administered orally once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol Pill
Description: 800mcg (four 200mcg pills) administered vaginally once 6-18 hours following ulipristal acetate
Study: NCT06255392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Apatinib Mesylate oral; each treatment cycle defined as 3 weeks (21 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine tablets
Description: Capecitabine tablets, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine Tartrate Oral
Description: For the first three courses: reasonable dosage with reference to guidelines. After 3 courses of medication, it is recommended to increase the dose of vinorelbine tartrate once a week. Each treatment cycle defined as 3 weeks (21 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin mesylate injection
Description: Eribulin, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: Gemcitabine, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel-albumin
Description: Paclitaxel-albumin, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).
Study: NCT05848479

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal bracing
Description: they will perform 3 times/week of static abdominal contraction for six weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal bracing
Description: they will perform 3 times/week of static abdominal contraction for six weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clamshell exercise
Description: Each women will be positioned in side lying on the floor, with the pelvis and the spine in neutral position, the hips will bent at 45° and the knees flexed to 90°. She will abduct the top knee as far as possible, while keeping the heels together, then return to the starting position , the position will be maintained for 5 seconds in an abduction state, and repeated 10 times, with rest for 1 minute to minimize muscle fatigue,they will perform 3 times/week fo 6 weeks
Study: NCT05115448

Intervention type: OTHER
Group type: OTHER
Intervention: Bevel Position
Description: During 6 dialysis sessions, cannulation was applied to the patients with the direction of the arterial needle in the antegrade direction and the conical tip facing upwards. In the next 6 dialysis sessions, cannulation was applied to the patients in an antegrade direction and with the conical tip facing down.

Intervention type: OTHER
Group type: OTHER
Intervention: Bevel Position
Description: During 6 dialysis sessions, cannulation was applied to the patients with the direction of the arterial needle in the antegrade direction and the conical tip facing upwards. In the next 6 dialysis sessions, cannulation was applied to the patients in an antegrade direction and with the conical tip facing down.